ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) […]

Continue Reading

TERRA BALCANICA CONFIRMS EPITHERMAL GOLD AND PORPHYRY COPPER TARGETS AT CEOVISHTE IN SERBIA AND CLOSES FIRST TRANCHE OF FINANCING

Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) is pleased to announce positive assay results from surface rock chip and soil sampling at its 80.4 km2 Ceovishte license in southern Serbia and closing of the 1st tranche of the previously announced non-brokered private placement financing of units (the ”Units”) for gross proceeds of $404,650 (the […]

Continue Reading

Cuppa Coffee Studios USA and UK Locomotive Entertainment completed comedic play “The Thwarting of Baron Bolligrew ”

Los Angeles based, Cuppa Coffee Studios USA and the UK’s Locomotive Entertainment have announced completion on the development on the “The Thwarting of Baron Bolligrew ”, a Robert Bolt comedic play, now realized as a 90 minute feature and given the tip of approval by Robert Bolt Ltd.   Bolt, the prolific, three time Academy Award winner ( Lawrence of Arabia, Dr. Zhivago and A Man for All Seasons ) was originally commissioned […]

Continue Reading

Databricks Ventures Invests in Data Security Leader Immuta

Strategic investment builds upon long-standing partnership and reinforces Databricks’ commitment to Immuta as its trusted partner for data security…   Immuta, a leader in data security, today announced a new strategic investment from Databricks Ventures, the investment arm of the data and AI company and pioneer of the lakehouse. The investment builds on a longstanding partnership between […]

Continue Reading

NevGold Intercepts Strongly Oxidized, Silicified Sandstone with Quartz Veining From Surface With Assays Pending

NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further drilling has intercepted strongly oxidized, silicified sandstone with quartz veining from surface at the Nutmeg Mountain gold project (the “Project”, “Nutmeg Mountain”) in Idaho. The Project hosts a 2020 historic Mineral Resource Estimate of 910,000 Indicated ounces of gold (43.5 Mt […]

Continue Reading

CEBINA Announces Positive Results of a Phase 2 Clinical Study with COVID-19 patients and Azelastine Nasal Spray Published in a Peer-Reviewed Scientific Journal

CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of the positive results of a Phase 2 clinical study that tested azelastine nasal spray as a new approach for reducing viral load in the nose of SARS-CoV-2 positive patients in the peer-reviewed journal Scientific Reports (1).   Vaccines have been a useful […]

Continue Reading

Skyharbour to Acquire 100% of South Dufferin Uranium Project from Denison Mines in the Athabasca Basin, Saskatchewan

Skyharbour Resources Ltd. (TSX-V: SYH)  (OTCQX: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that it has acquired 100% of the South Dufferin Uranium Project (“South Dufferin” or the “Project”) from Denison Mines Corp. (“Denison”). The South Dufferin Project comprises 12,282 hectares (30,349 acres) over nine claims in the Athabasca Basin, which is host to the highest-grade uranium deposits in the […]

Continue Reading

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today presented preclinical data supporting the development of a computationally-derived amyloid-beta (Aβ) vaccine for AD […]

Continue Reading